ABSTRACT
INTRODUCTION
Antisense oligonucleotides (AOs) contain 10-30 nucleotides complementary to a specific sub-sequence of an mRNA target, which are designed to bind to targets by standard Watson-Crick base pairing rules. The bound duplex is a substrate for RNase-H which cleaves the RNA while leaving the AO intact. The AO inhibits gene expression in a specific and reversible manner, a process termed 'Gene knock-down'. For a comprehensive review * To whom correspondence should be addressed.
of the topic see (Crooke, 2000) .
There are many laboratory-based strategies for selecting AOs. One of the most successful is the 'gene-walk' approach, in which 15 or more AOs are evaluated for a gene in order to find a sufficiently effective AO. A faster method selects mRNA regions that are accessible to RNase-H cleavage and therefore more likely to be an effective site for AOs (Ho et al., 1998) . Milner et al. (1997) use an array of 1-17mer oligodeoxynucleotides to measure heteroduplex formation potential. In general the experimental approaches are time consuming and expensive.
AO design is not as simple as synthesizing an AO that is complementary to the mRNA. Factors such as likelihood to form hairpin or dimer structures and the accessibility of the region of mRNA targeted are important factors in AO efficacy. AOs are generally selected to avoid these problems, however even for careful designs the success rate is low, typically 20% or less of AOs are effective (Myers and Dean, 2000) .
There are many examples in the literature of experimental groups attempting to correlate AO sequence properties with efficacy. A correlation between binding energy (AO-RNA) and efficacy has been observed (Ho et al., 1996 (Ho et al., , 1998 . Particular target secondary structures have been shown to correlate with efficacy (Vickers et al., 2000; Bacon and Wickstrom, 1991; Laptev et al., 1994) . However the correlations are not consistently detected across studies. This variation can be due to many factors including biases in the selection of the AOs, varying experimental conditions, or, in cases where computational RNA folding prediction was used, limitations in the structure prediction methods.
The properties thought most likely to affect AO efficacy can be divided into classes: (a) binding energy parameters consisting of RNA-AO binding energy, measures of accessibility of the RNA to the AO and AO-AO binding energies (dimerization and hairpin energy); (b) sequence motifs (these could affect the AO or RNA structure, RNase-H recognition, half-life); and (c) 'Other'-cellular uptake, protein interactions, etc. AO selection can be based on either experimental or theoretical approaches (for a review, see Sczakiel, 2000) . Computational approaches to AO design have so far focused on prediction of the structure of the target mRNA and from this deriving the accessibility of target regions (e.g. Sczakiel et al., 1993; Mathews et al., 1999; Patzel et al., 1999; Walton et al., 1999; Amarzguioui et al., 2000; Song et al., 2000; Scherr et al., 2000; Sczakiel, 2000; Toschi, 2000; Ding and Lawrence, 2001) . Perhaps the most successful method is that of Ding and Lawrence (2001) , using a statistical sampling of secondary structures to predict accessible regions to find effective AOs for rabbit β-globin. In general, methods have not been evaluated on a broad range of gene targets. Another method is to look for motifs that occur more often in effective AOs. In a survey of 42 AOs with high efficacy from selected studies, 20 contain the TCCC motif. 10 sequence motifs have been identified with a correlation to AO efficacy by Matveeva et al. (2000) . While no proof of mechanism has been reported, possible explanations include cellular uptake, preferential binding to RNase-H, stability of the DNA:RNA duplex and effect of motifs on AO/target structure.
The challenge is hence to discover general principles that hold across all AO studies. One approach to discover such principles is to explore a diverse range of sequence properties and incorporate the factors that affect AO efficacy into a computational model for AO design. This requires both a database of tested AOs, such as that produced by Giddings et al. (2000) , and machine learning methods of model building. The database should be based on large AO screening experiments to ensure comparability. The model must be able to handle the inherent noise in the system, whilst being able to find the complex relationship between the various AO properties and the AO's efficacy.
A popular machine learning approach that effectively handles noise and complex relationships in a robust way is the artificial neural network (NN). For an introduction to neural networks see Baldi and Brunak (1998) and Rumelhart et al. (1986) . In this paper we present a data compilation of AOs with experimentally determined efficacy, and apply a neural network model to predict AO efficacy.
METHOD

Database
A database was assembled from a selection of AO publications. Published data was incorporated for which: (a) at least 6 AOs were tested under the same experimental conditions, although more than one gene target were allowed; (b) efficacy of the AOs were presented as a percentage of the control level of the target gene expression, either as RNA or protein. No papers were reported matching these criteria before 1990, as is consistent with Giddings et al. (2000) . Accompanying this data is the full RNA sequence and accession number (where available) together with positional coordinates of the AOs and the position of the coding sequence. Publication details, cell line used and the chemistry of the AOs (unmodified, phosphorothioate, phosphoramidite) were also recorded in the database. The database consists of 490 oligonucleotides from 20 studies testing AO efficacy on 16 genes. The essential information in the database is AO sequence and efficacy expressed as (100%-[% of control expression])/100; efficacies range between 0 and 1, representing no inhibition and complete inhibition of gene expression respectively. A summary of the contents is shown in Table 1 . For the cases where the same AO is tested in two different laboratories, or twice by the same laboratory the average efficacy is used.
Derived parameters as network input
A set of parameters was derived from the information contained in the AO sequence collection, including values for: (1) base composition (Number of A/C/G/T, %GC content): (2) RNA-AO binding properties (binding energy, enthalpy, entropy): (3) RNA-AO terminal properties (3' binding energy, 5' binding energy); (4) AO-AO binding properties (Hairpin energy and quality, Dimer energy); and (5) 9 of the 10 verified sequence motifs correlated with efficacy from Matveeva et al. (2000) . Binding energy calculations were completed using thermodynamic parameters from Sugimoto et al. (1995) . The calculation of dimer energy was made using an ungapped alignment with stacking energies taken from Sugimoto et al. (1996) and a uniform penalty 0.5 for mismatches. Hairpin energy was calculated using mfold (Walter et al., 1994) . Hairpin quality (the number of hydrogen bonds in the stem of the stem-loop structure) is calculated using the Stemloop module of the GCG Package (Devereux et al., 1984) . Parameters describing cellular uptake and protein interactions were not included, as we have no explicit way of modeling them.
Efficacy values were first rounded such that all efficacy values are between [0,1], negative efficacy levels occur when the target gene is up-regulated with respect to the level of control. Any biological data set contains noise, however careful the collection method. We strive to reduce this noise by removing 93 data points with efficacy less than 0.05. The reasoning is that there are many factors that can cause an experiment or part of the experiment to fail (giving efficacy <0.05), while there are few situations that can cause high efficacy values to be so noisy. This 'noise' is illustrated by observing the correlation between dH/length and efficacy, which is −0.11 using the full data set and improves to −0.19 when removing AOs in the range 0-0.05. It is also interesting to note that for binding Lee et al. (1995) energy (delta G) the correlation coefficient is zero for the set of AOs with efficacy 0-0.5, while a correlation coefficient of −0.17 is observed for the AOs with efficacy in 0.5-1.0. This observation held for a large number of the 23 AO properties explored, with correlations increasing with removal of low efficacy AOs. Several strategies were employed to determine the desirable input parameters for the network. First all potential parameters were derived. Next two strategies were used to create input parameter sets: (A) removal of highly redundant parameters using the following method. If the correlation between two parameters was above a defined cutoff the parameter with the lowest correlation coefficient with efficacy was removed. This procedure is repeated until no two parameters are correlated above the defined cutoff. Two sets (denoted b and c) were generated using 0.8 and 0.65 as cutoff values; and (B) correlated data set. Only parameters with a high correlation with efficacy were used. Two sets (denoted d and e) were generated using 0.1 and 0.15 as cutoffs for the correlation coefficients (data not shown.). The parameter combinations are presented in Table 2 .
Neural Network
A schematic view of the neural network (NN) model for predicting AOs is shown in Figure 1 . The neural network source code is based on C code written by Dr Mikael Boden, with additions made by the authors for the simulation requirements. For the current application, inline training was employed using a standard sigmoid activation function with backpropagation. For all simulations the learning rate was set to 0.2, with momentum = 0.5. The presentation order of the input vectors remained constant throughout training. The continuous input nodes of the network were normalized so that 95% of values for each node were in the range [0, 1]. Motif presence/absence was encoded in a binary fashion, 0 denotes no motif, while 1 denotes one or more occurrences of the motif.
Early stopping and cross validation
For our NN simulations we define three sets of AOs: a training set, an early stopping set and a test set. The early stopping set is used in order to decide when to stop the training, and should not contain AOs similar to those in the test set. After this point is reached the test set (as yet unseen by the network) is used to test the accuracy of the network. An example is shown in Figure 2 . We tested several different early stopping set sizes (20, 40, 60, 80-data not shown), and selected 40 as the early stopping set size.
When considering a multitude of cross-validation methods we asked ourselves the question: 'How related is the so that the scale was independent of the number of AOs. The results for the normalized rank correlation in each category are shown in Table 3 . No correlation was found between AOs greater than 50 bp apart, hence we selected this cut-off for further testing. This approach allows us to use more of the data points in the training of the model than the standard method of cross-validation, where all AOs from the same gene are disallowed from the training and early stopping sets. Our method is illustrated in Figure 3 . We trained each network until the error on the early stopping set reached minimum. We then use this network to predict the test example's efficacy. Network performance is measured as the Spearman rank correlation for the set of all pairs of test examples (observed, predicted) . In all cases we averaged the results from 10 networks to improve the robustness of the results.
RESULTS
We compiled a database of 490 AO molecules from 20 AO screening studies on 16 different genes, see Table 1 . The database, called AOdb, contains all the relevant data on the AO sequences and their efficacy, as well as the corresponding cDNA sequences. AOdb can be used as a resource for testing models for AO prediction, and is available on request. We used those AOs in AOdb with position information to train NN models for predicting AO efficacy. We explored a multitude of architectures, using previously described input parameter sets, and varied the number of hidden units. The best architecture was observed using input set (d), with 11 hidden units. The resulting Spearman rank correlation (observed vs predicted) was 0.30 ( p = 10 −8 ).
How much confidence should one have in a given prediction? The distribution of observed efficacies compared to predicted efficacies (Figure 4) shows that AOs predicted to have high efficacy are more reliable than low efficacy predictions. We can quantitate the reliability by looking at predictions above a defined threshold X and observe how many are correctly predicted to have an observed efficacy above a threshold Y . Using the 10-ensemble net- works gives the following result: Of all AOs predicted above 0.6, 92% were observed to have an efficacy above 0.5. Of these, 50% were highly effective (having an observed efficacy above 0.8; see Table 4 ). This is considerably higher than randomly picked AOs from AOdb, which gives 52% above 0.5 efficacy and 17% above 0.8. For comparison we tested a more standard method of cross-validation, involving removing all AOs targeting the same gene as the test AO from the training and early stopping sets. The resulting performance was better when looking at the rank correlation statistic (0.34) while AOs predicted above 0.8 efficacy showed similar results, while results for predicting AOs with efficacy above 0.5 were diminished (data not shown).
How many effective AOs can one expect to predict in a stretch of DNA? We applied the model to a set of 17 randomly chosen mRNA sequences, with a total length of 55 750 bp. No sequences showed homology to any genes in AOdb using BLAST (Altschul et al., 1997) with an evalue cutoff of 10.0. The 327 ensembles generated during training processed the sequences. AOs of high efficacy were predicted at the rate of 12 and 51 AOs per 1000 bp, using a cutoff of 0.6 and 0.5 respectively. This suggests that the method is useful for AO selection in practice. Obviously, because the model is tuned to be stringent, it does not find all effective AOs. In fact, the false negative rate is high-on AOdb it is over 80%. As AOdb only contains a sparse sampling of AOs from each gene, the true false negative rate is unknown, but it is clearly very high. This is however acceptable if the goal is to find a practical number of effective AOs in a given gene while avoiding false positives.
DISCUSSION
While the proposed mechanisms by which AOs inhibit gene expression are relatively simple, the efficacy of a given AO is determined by many complex factors of which we have limited understanding. Antisense studies have produced small correlations between one parameter (e.g. RNA structure, motif content, binding energy) and efficacy. However these correlations are sometimes conflicting and vary between studies. Our method of model generation relies on a broad data set from many studies and target genes to generate a robust system for predicting effective AOs for any given gene.
We removed AOs within 50 bp when training, based on observation that such pairs have some correlation between their efficacies. Yet there are many examples of overlapping AOs that have strikingly different efficacies. An answer to this question and greater understanding of the AO prediction problem requires both a data set containing many series of overlapping AOs and methods for extracting explicitly structural information from the target region. RNA structural information is implicit in our model, using motif content and energy parameters. Subsequent studies of RNA folding combined with more detailed data sets of overlapping AOs have the potential to greatly increase our understanding of AO design.
The input parameters used in the model contains many of the motifs found by Matveeva and colleagues , which is expected due to the similarity of the data sets used. Perhaps surprising is the lack of correlation between dimer energy and efficacy. An explanation for this could be a bias in AOdb-one would expect the majority of AOs in AOdb to be designed to avoid high dimer energies. Hairpin energy had the lowest correlation of any parameter used in the model, again this lower correlation could relate to a pre-screening process used by experimentalists when designing AOs. The highest correlations found were generally energy (directly as binding energy, indirectly as %GC content) or motif based. Energy terms can be expected to be good indicators as binding is a critical part of this antisense process, and indeed a number of studies in the area focus on the thermodynamics of the process. The reasons for motif content being a good predictor are unknown, but several hypotheses exist (see Introduction).
Because of the complexity and multitude of factors affecting AO efficacy, we were unable to reach a higher correlation coefficient between predicted and observed efficacy than 0.30 for all data points. However, most of this variability is found for AOs with predicted efficacies in the range 0-0.5, while AOs in the upper range show less variation (see Figure 3) . Therefore the suitable application of this model is the prediction of highly effective AOs. The model can predict effective AOs (>50% inhibition of gene expression) with a success rate of 87% at 51 predicted high efficacy AOs per 1000 bp. A higher success rate can be obtained at the cost of a lower prediction rate.
When comparing predicted efficacy values to experimental studies there are several issues that should be noted. Firstly the model does not predict all AOs of high efficacy, but a subset of them. This is an issue of sensitivity versus accuracy. We consider that as long as a sufficient number of high efficacy AOs are predicted per gene then we should be as selective as possible. It is however difficult to validate this using published studies. We will often identify AOs that have not been tested, while known AOs of high efficacy will not necessarily be picked up by our model. The ideal scenario for testing the method would be to validate the predicted AOs in vivo and/or in vitro.
The model often produces a curve with adjacent AOs having correlated predictions, i.e. it tends to predict regions of similar efficacy. This correlation is mainly caused by regions of similar composition and by motifs being shared by overlapping AOs.
Our model can be used in combination with other methods to strengthen our predictions. A specificity screen to check for perfect or near-perfect matches to other target genes helps us avoid non-specific AOs. A more explicit incorporation of (predicted) accessible sites in the target RNA should improve accuracy if they are sufficiently reliable. A web server interface to the model is available at http://www.cgb.ki.se/AOpredict.
